Company: MDCXW
Filing Date: 2025-09-19
Form Type: DRS
Source: 0001062993-25-015719
Chunk: 255

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-19
Form: DRS
Chunk 255
---
 notes                                 |   |                         - |   |     |   |  5,172,500 |   |
| Proceeds from exercise of warrants                                          |   |                   977,398 |   |     |   |          - |   |
| Costs to issue Debentures                                                   |   |                   (54,582 | ) |     |   |          - |   |
| Cash paid for financing costs in connection with SEPA                       |   |                  (297,783 | ) |     |   |          - |   |
| Net cash provided by financing activities                                   |   |                14,915,048 |   |     |   | 10,642,500 |   |
| Net increase in cash and cash equivalents during the period                 |   |                 5,505,223 |   |     |   |  6,688,861 |   |
| Cash and cash equivalents, beginning of the year                            |   |                 4,164,323 |   |     |   |  1,719,338 |   |
| Cash and cash equivalents, end of the period                                |   |                 9,669,546 |   |     |   |  8,408,199 |   |
| Supplemental disclosure of non-cash investing and financing activities:     |   |                           |   |     |   |            |   |
| Right-of-use assets obtained in exchange for lease liabilities              | $ |                         - |   |     |   |    356,805 |   |
| Issuance costs included in accounts payable                                 | $ |                   271,618 |   |     |   |          - |   |
| Deferred issuance costs on issued shares related to SEPA                    | $ |                   300,000 |   |     |   |          - |   |

<div align='center'>The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

F-29

CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD.PURSUANT TO 17 C.F.R. SECTION 200.83

MEDICUS PHARMA LTD.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</div>

1.Description of business

Medicus Pharma Ltd. (the "Company"), formerly Interactive Capital Partners Corporation, is a clinical stage, multi-strategy, life sciences, biotech company focused